Jesper Kjerulff leads again
PharmNovo is very pleased to inform you that our former project leader, Jesper Kjerulff has returned as project leader and Chief Operations Officer.
Jesper has extensive knowledge and experience of working strategically and successfully with the drug development process from preclinical through phase I,II and III, on to registration and launch. Jesper has an intimate knowledge of the PN6047 project from his former role, and it will be a privilege for all of us at PharmNovo to have Jesper back in the team continuing the journey with PN6047.
Jesper Kjerulff leads again
PharmNovo is very pleased to inform you that our former project leader, Jesper Kjerulff has returned as project leader and Chief Operations Officer.
Jesper has extensive knowledge and experience of working strategically and successfully with the drug development process from preclinical through phase I,II and III, on to registration and launch. Jesper has an intimate knowledge of the PN6047 project from his former role, and it will be a privilege for all of us at PharmNovo to have Jesper back in the team continuing the journey with PN6047.
Latest news
View all
Watch PharmNovo at LSX in Lisbon
Take the opportunity to listen to Per von Mentzer, CEO, presenting PN6047 at the LSX World Europe congress in Lisbon, March 2026. Learn how PharmNovo is shaping a new approach to pain relief with the goal to prove that powerful pain treatment doesn’t have to come with the cost of addiction. Discover how the company’s lead candidate PN6047, delivers effective pain relief without activating the mu-opioid receptor and avoiding the addiction risks associated with conventional opioids. The Phase II-ready Delta Opioid Receptor Agonist (DORA) with first-in-class potential, PN6047 represents a safer, non-addictive approach targeting a neuropathic pain market that is expected to double until 2033 and reach 13 bEUR.
Read more
Capsules ready for Phase IIa Study
PharmNovo is pleased to announce that that the company has completed drug product manufacturing for its lead candidate PN6047. This is an important milestone as the company prepares for its upcoming Phase IIa proof-of-concept study in neuropathic pain.
Read more
Welcome on Board
As the company prepares for the next phase of clinical development, the new Board composition strengthens our strategic capabilities ahead of Phase II development of our lead candidate, PN6047.
Read more
